Vishal Pawar
Independent Researcher
Maharashtra, India
Abstract
Psoriatic arthritis (PsA) is a chronic, inflammatory arthropathy associated with psoriasis that manifests in diverse clinical forms and affects the joints and entheses. The interleukin-23 (IL-23)/Th17 axis plays a pivotal role in the immunopathogenesis of PsA, making it a compelling target for biological therapy. Tremfaya, a monoclonal antibody targeting the p19 subunit of IL-23, demonstrated early efficacy and tolerability in PsA patients during initial Phase III clinical trials. This extension study evaluates the long-term immunomodulatory impact of Tremfaya on the IL-23 signaling pathway over a 96-week treatment window. Through molecular biomarker profiling, clinical outcome measures, and radiographic progression assessments, the study investigates sustained therapeutic responses and immunological alterations in PsA patients receiving continued Tremfaya therapy. The findings reinforce the centrality of IL-23 in PsA pathophysiology and support the extended clinical application of Tremfaya in disease modification strategies.
Keywords
Psoriatic arthritis, Tremfaya, IL-23 pathway, long-term therapy, Phase III extension study, immunomodulation, biologics, Th17, psoriasis, cytokine inhibition
References
- Reich K, Armstrong A W, Foley P, et al. Efficacy and safety of guselkumab, an anti–interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate-to-severe psoriasis (VOYAGE 2). J Am Acad Dermatol. 2017;76(3):418-431. doi:10.1016/j.jaad.2016.11.042 ncbi.nlm.nih.gov
- Gaffen S L, Jain R, Garg A V, Cua D J. The IL-23–IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585-600. doi:10.1038/nri3707 ncbi.nlm.nih.gov
- Tang C, Chen S, Qian H, Huang W. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology. 2012;135(2):112-124. doi:10.1111/j.1365-2567.2011.03522.x ncbi.nlm.nih.gov
- Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin-12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373(9664):633-640. doi:10.1016/S0140-6736(09)60140-9 ncbi.nlm.nih.gov
- McInnes I B, Mease P J, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137-1146. doi:10.1016/S0140-6736(15)61134-5 ncbi.nlm.nih.gov
- Yang X O, Chang S H, Park H, et al. Regulation of inflammatory responses by IL-17F. J Exp Med. 2008;205(5):1063-1075. doi:10.1084/jem.20071978 ncbi.nlm.nih.gov
- Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715-725. doi:10.1016/S1074-7613(00)00070-4 ncbi.nlm.nih.gov
- Gordon K B, Duffin K C, Bissonnette R, et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015;373(2):136-144. doi:10.1056/NEJMoa1501646 ncbi.nlm.nih.gov
- Ritchlin C T, Colbert R A, Gladman D D. Psoriatic arthritis. N Engl J Med. 2017;376:957-970. doi:10.1056/NEJMra1505557
- Mease P J. Inhibition of interleukin-17, interleukin-23 and the T-helper 17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol. 2015;27(2):127-133. doi:10.1097/BOR.0000000000000147